Australia Stock Exchange release from PROTEOMICS INTER : Clinical utility study shows benefit of PromarkerD testing
17/10/2021 23:28
Australia Stock Exchange release from PROTEOMICS INTER PIQ.AX : Clinical utility study shows benefit of PromarkerD testing
Recent news on Proteomics International Laboratories
See all newsBrief: Proteomics International Laboratories Launches Share Purchase Plan To Raise Up To A$5 MLN
Australia's Proteomics slips to four-month low on discounted share sale plan
Brief: Proteomics International Laboratories Posts FY Loss Attributable A$8.6 Million
Brief: Proteomics International Laboratories Signs Agreement With Healius For Promarker Portfolio
Australia's Proteomics International soars on distribution deal with Healius